Why did GAAP EPS rise so sharply, and is that growth sustainable?

GAAP diluted EPS rose to $2.43 from $1.00 mainly because Q3 2024 included a $1.75 billion IPR&D impairment that did not repeat, and Q3 2025 benefited from about $400 million of royalty, contract and other revenue tied to a prior IP sale that management does not expect to recur. Those items are not indicators of ongoing performance. Non-GAAP EPS growth of 22% to $2.47 is more representative, though it also benefited from that one-time revenue and lower acquired IPR&D spending.

What does the Biktarvy patent settlement mean for investors?

Settlements with Lupin, Cipla and Laurus set the earliest U.S. generic entry date for full-dose Biktarvy at April 1, 2036, subject to standard acceleration provisions. That is more than two years later than the prior December 2033 projection and materially extends the franchise's runway, which is Gilead's largest product by sales at $3.7 billion in the quarter.

Why did full-year guidance change, and what are the key drivers?

Non-GAAP diluted EPS guidance narrowed upward to $8.05–$8.25 from $7.95–$8.25, and product sales guidance was nudged up to $28.4–$28.7 billion. GAAP EPS guidance rose significantly to $6.65–$6.85, reflecting a lower projected GAAP effective tax rate of about 16% (from about 21%), which includes an October 2025 settlement with a tax authority related to a prior legal entity restructuring. Veklury guidance is unchanged at $1.0 billion.

How exposed is Gilead to declining COVID-19 demand and Cell Therapy competition?

Veklury fell 60% year over year to $277 million, and full-year guidance of about $1.0 billion implies a steep ongoing decline from prior levels, so this remains a headwind to reported product sales. Cell Therapy sales fell 11% to $432 million, with Yescarta down 10% and Tecartus down 15%, reflecting competitive pressure. Excluding Veklury, product sales grew 4%, indicating that the core HIV and Liver Disease businesses are offsetting these declines.

How strong is Gilead's balance sheet and capital allocation?

Gilead generated $4.1 billion of operating cash flow in Q3 and $6.7 billion year to date, with free cash flow of $6.3 billion over nine months. It returned about $1.4 billion to shareholders in the quarter through dividends ($1.0 billion) and buybacks ($435 million). Cash and marketable securities were $9.4 billion, and total long-term liabilities were $24.8 billion, down from $27.7 billion at year-end 2024. Moody's affirmed its A3 rating and moved the outlook to positive, and the Board declared a $0.79 quarterly dividend for Q4 2025.

GILD 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed October 30, 2025. Cited figures are marked; the original filing is the authoritative source.

Gilead Sciences reported third quarter 2025 results on October 30, 2025, with total revenues up 3% to $7.8 billion^a and GAAP diluted EPS of $2.43, versus $1.00 a year earlier.

The headline GAAP comparison is flattered by a $1.75 billion^b IPR&D impairment in Q3 2024 that did not recur, plus a roughly $400 million increase in royalty, contract and other revenue tied to a prior intellectual property sale that management does not expect to recur. Underlying product sales were flat-to-down at $7.3 billion (down 2%), but product sales excluding Veklury grew 4% to $7.1 billion, driven by HIV (Biktarvy up 6%, Descovy up 20%) and Livdelzi in Liver Disease, partially offset by Cell Therapy declines of 11%. Non-GAAP diluted EPS rose 22% to $2.47, a more representative measure of operating performance, which benefited from the one-time revenue and lower acquired IPR&D spending.

Guidance was raised. Full-year 2025 product sales are now $28.4 to $28.7 billion^c (from $28.3 to $28.7 billion), and non-GAAP diluted EPS is $8.05 to $8.25 (from $7.95 to $8.25). GAAP diluted EPS guidance rose meaningfully to $6.65 to $6.85 from $5.85 to $6.15, largely reflecting a tax-related effect and a lower GAAP effective tax rate assumption of about 16%.

Management's tone is constructive, citing a strong start for Yeztugo (lenacapavir PrEP), the Biktarvy patent settlements that push expected U.S. generic entry to April 2036 (more than two years later than the prior December 2033 projection), and Moody's outlook upgrade to positive. Key risks remain: Veklury sales collapsed 60% as COVID-19 hospitalizations declined, Cell Therapy faces ongoing competitive pressure, Trodelvy's 1L mTNBC data (ASCENT-03) is not yet an approved setting, and the company still carries about $9.4 billion^d in cash and securities against $24.8 billion of long-term liabilities.

Operating cash flow was $4.1 billion in the quarter, with $1.0 billion in dividends and $435 million in share repurchases. The company also announced the Interius acquisition and a planned $32 billion U.S. investment through 2030.

02—Key points

Key Highlights

Q3 2025 total revenues rose 3% to $7.8 billion; product sales fell 2% to $7.3 billion, but product sales excluding Veklury grew 4% to $7.1 billion.
GAAP diluted EPS was $2.43 (vs. $1.00), inflated by the absence of a $1.75 billion Q3 2024 IPR&D impairment and a roughly $400 million non-recurring royalty/other revenue increase; non-GAAP diluted EPS was $2.47 (up 22%).
Full-year 2025 guidance raised: product sales $28.4–$28.7 billion, non-GAAP diluted EPS $8.05–$8.25 (low end raised from $7.95), and GAAP diluted EPS $6.65–$6.85 (from $5.85–$6.15).
Biktarvy U.S. generic entry now expected no earlier than April 1, 2036, after settlements with Lupin, Cipla and Laurus, extending exclusivity more than two years versus the prior December 2033 projection.
Veklury sales declined 60% to $277 million on lower COVID-19 hospitalizations, while Cell Therapy sales fell 11% to $432 million amid competitive pressure.
Strong HIV franchise momentum: total HIV sales rose 4% to $5.3 billion, Descovy grew 20%, and Yeztugo (lenacapavir PrEP) received a favorable CDC recommendation and EU approval as Yeytuo.
Cash generation and capital returns: $4.1 billion operating cash flow and $3.96 billion free cash flow in Q3; $1.0 billion dividends paid and $435 million in buybacks; cash and marketable securities of $9.4 billion; Moody's outlook raised to positive.

03—Questions

Frequently Asked Questions

Why did GAAP EPS rise so sharply, and is that growth sustainable?
GAAP diluted EPS rose to $2.43 from $1.00 mainly because Q3 2024 included a $1.75 billion IPR&D impairment that did not repeat, and Q3 2025 benefited from about $400 million of royalty, contract and other revenue tied to a prior IP sale that management does not expect to recur. Those items are not indicators of ongoing performance. Non-GAAP EPS growth of 22% to $2.47 is more representative, though it also benefited from that one-time revenue and lower acquired IPR&D spending.
What does the Biktarvy patent settlement mean for investors?
Settlements with Lupin, Cipla and Laurus set the earliest U.S. generic entry date for full-dose Biktarvy at April 1, 2036, subject to standard acceleration provisions. That is more than two years later than the prior December 2033 projection and materially extends the franchise's runway, which is Gilead's largest product by sales at $3.7 billion in the quarter.
Why did full-year guidance change, and what are the key drivers?
Non-GAAP diluted EPS guidance narrowed upward to $8.05–$8.25 from $7.95–$8.25, and product sales guidance was nudged up to $28.4–$28.7 billion. GAAP EPS guidance rose significantly to $6.65–$6.85, reflecting a lower projected GAAP effective tax rate of about 16% (from about 21%), which includes an October 2025 settlement with a tax authority related to a prior legal entity restructuring. Veklury guidance is unchanged at $1.0 billion.
How exposed is Gilead to declining COVID-19 demand and Cell Therapy competition?
Veklury fell 60% year over year to $277 million, and full-year guidance of about $1.0 billion implies a steep ongoing decline from prior levels, so this remains a headwind to reported product sales. Cell Therapy sales fell 11% to $432 million, with Yescarta down 10% and Tecartus down 15%, reflecting competitive pressure. Excluding Veklury, product sales grew 4%, indicating that the core HIV and Liver Disease businesses are offsetting these declines.
How strong is Gilead's balance sheet and capital allocation?
Gilead generated $4.1 billion of operating cash flow in Q3 and $6.7 billion year to date, with free cash flow of $6.3 billion over nine months. It returned about $1.4 billion to shareholders in the quarter through dividends ($1.0 billion) and buybacks ($435 million). Cash and marketable securities were $9.4 billion, and total long-term liabilities were $24.8 billion, down from $27.7 billion at year-end 2024. Moody's affirmed its A3 rating and moved the outlook to positive, and the Board declared a $0.79 quarterly dividend for Q4 2025.

04—Continue

← View all 8-K filings